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ABSTRACT
Objectives: Mean platelet volume (MPV) is assosiated with platelet function and activation. Increased MPV values indicate elevated platelet functions 
and are assosiated with inflammation. We investigated postoperative MPV changes of the patients with osteoarthritis (OA) after total hip arthroplasty.
Material and Method: This retrospective study was conducted on 813 patients with coxarthrosis and 152 patients without primary coxarthrosis (control 
group). The patients were divided into two groups. The first group was treated with total hip arthroplasty (n=312) and the second with conservative 
methods (n=501). MPV, ESR, and CRP were eveluated. Early phase (up to 10 days after the operation), and late phase (>30 days postoperation) data of 
the patients with total hip arthroplasty were recorded.
Results: Statisticaly significant differences on the mean MPV values were found between control and conservative treatment groups, and also 
between control and early phase surgical treatment groups (p=0.001 and p=0.005, respectively). No statistically significant difference was determined 
between control and late phase surgical treatment groups (p=0.796). Statisticaly significant differences were determined in the mean MPV values 
between conservative treatment and late phase surgical treatment groups (p=0.001), but no statistically significant difference was determined between 
conservative treatment and late phase surgical treatment groups (p=0.057).
Conclusion: We think that changes in serum MPV values can be used as a predictive marker for inflammatory reactivation following total hip 
replacement surgery. The serum MPV values obtained in our study may guide future studies investigating inflammatory reactivation in hip 
arthroplasty surgeries
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ÖZ
Total kalça artroplastisi sonrası inflamatuar reaktivasyonun bir belirteçi olarak ortalama trombosit hacmi
Amaç: Ortalama trombosit hacmi (MPV) trombosit fonksiyonu ve aktivasyonu ile ilişkilidir. Artan MPV değerleri, trombosit fonksiyonlarının yükseldiğini 
ve inflamasyonu ile birlikteliği göstermektedir. Total kalça artroplastisi sonrası osteoartritli (OA) hastaların postoperatif MPV değişikliklerini araştırdık.
Gereç ve Yöntem: Bu retrospektif çalışma, koksartrozlu 813 hasta ve primer koksartrozu olmayan 152 hasta üzerinde yapıldı (kontrol grubu). 
Hastalar iki gruba ayrıldı. Birinci grup total kalça artroplastisi (n=312) ve ikinci grup konservatif yöntemlerle (n=501) tedavi edildi. MPV, ESR ve CRP 
değerlendirildi. Total kalça artroplastisi uygulanan hastaların erken evre (operasyondan sonra 10 güne kadar) ve geç evre (operasyondan 30 gün 
sonrası) verileri kaydedildi.
Bulgular: Kontrol grubu ile konservatif tedavi grubu arasında ve kontrol grubu ile erken evre cerrahi tedavi grubu arasında istatistiksel olarak anlamlı 
ortalama MPV değerleri bulundu (sırasıyla p=0.001 ve p=0.005). Kontrol grubu ile geç evre cerrahi tedavi grubu arasında istatistiksel olarak anlamlı 
fark bulunmadı (p=0.796). Konservatif tedavi grubu ile geç evre cerrahi tedavi grubu arasında ortalama MPV değerleri istatistiksel olarak anlamlı 
bulundu (p=0.001), ancak konservatif tedavi grubu ile geç evre cerrahi tedavi grubu arasında istatistiksel olarak anlamlı fark yoktu (p=0.057).
Sonuç: Total kalça protezi ameliyatı sonrası inflamatuar reaktivasyou belirlemeye yönelik yeni çalışmalarda belirlediğimiz MPV değerlerindeki 
değişikliklerin katkı sağlayacağını düşünüyoruz.
Anahtar kelimeler: Ortalama trombosit hacmi, inflamatuar belirteç, sinovyal doku, aseptik gevşeme
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 INTRODUCTION
 Osteoarthritis (OA) is a common degenerative joint 
disease, in which the hip joint is often affected (1,2). Localized 
and asymptomatic synovitis mostly coexist with degenerative 
process of OA. Localized synovial inflammatory and 
proliferative changes may cause pain and joint dysfunction. 
Activated synovium disrupts other tissues of joint and 
extracellular matrix of cartilage. This disruption accelerates 
progression of OA. The severity of synovial reaction is 
associated with structural and metabolic factors of joints and 
disease duration. The inflammatory process contributes to 
progression and development of the disease (3-7). Peripheral 
blood platelet count is a marker for inflammatory process (8). 
Additionally, C reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) are used as markers of acute phase 
response (9-13). Mean platelet volume (MPV) is a parameter 
of complete blood count (CBC) and is associated with platelet 
function and activation. The size of platelets increase when 
activated and secrete inflammatory factors such as cytokines, 
chemokines, and coagulation factors. Increased MPV values 
indicate elevated platelet functions and are associated with 
inflammation (14). Some recent studies suggest that MPV can 
be used as a marker for determination of prognosis and 
severity of inflammatory systemic diseases (15-18).
 Normally synovial fluid is essential for cartilage and 
joint functions. Synovial fluid increase in the joint is an 
indication of synovial activation (19). Aseptic loosening and 
periprosthetic osteolysis may be associated with increased 
synovial fluid in the joints of patients with total hip 
arthroplasty (19,20). Elevated synovial fluid causes aseptic 
loosening by factors that regulate bone turnover (21). In 
management of total hip arthroplasty sufficient excision of 
joint capsule, synovium, and other pathological tissues are 
required for implant stability. However, sufficient removal 
of these tissues cannot be made during surgery.
 In this study, we aimed to investigate postoperative MPV, 
ESR and CRP changes of patients with OA after total hip 
arthroplasty.
 MATERIAL AND METHOD
 This retrospective study was conducted on 813 patients 
with grade IV primary coxarthrosis and 152 participants with 
similar demographic features without primary coxarthrosis 
(control group) who were admitted to our physical therapy 
and rehabilitation or orthopedics and traumatology clinics 
between June 2006 and March 2013.
 Patient’s positive for rheumatoid factor and anti-CCP or 
with chronic inflammatory diseases (such as ankylosing 
spondylitis or rheumatoid arthritis), systemic diseases (such 
as hypercholesterolemia, hypertension, diabetes mellitus, 
myocardial infarction, stroke, peripheral artery disease), 
active infection, a history of term medication, trauma to the 
hip and smoking were excluded from the study. Also, 
patients, whose records for direct hip radiographs, CBC, 
MPV, ESR, and CRP values could not be retrieved were 
excluded.
 All patients were operated with modified Gibson incision. 
The joint capsule and periarticular tissues were excised 
before implantation. All patients received polyethylene 
insert and no cement was used.
 The patients were divided into two groups. One group 
were treated with total hip arthroplasty (n=312) and the other 
with conservative methods (n=501). The age, sex, laboratory 
values and X-ray findings of the patients were evaluated. 
CBC, MPV, ESR, CRP values and direct anterior-posterior 
X-ray radiograph of the hips were evaluated. The rating of 
osteoarthritis on the X-rays was made according to Kellgren-
Lawrence scale (22). Early phase (up to postoperative 10 
days), and late phase (after postoperative 30 days) data of the 
patients with total hip arthroplasty were recorded. 
 Statistical Analysis
 SPSS (Statistical Package for the Social Sciences) 
software 17.0 (SPSS Inc, Chicago, IL, USA) was used for all 
analyses. Kolmogorov-Smirnov and Levene tests were used 
to analyze distribution and homogeneity of data. Statistical 
comparison of four groups was made by the one way ANOVA 
test. Bon- Ferroni test was used to compare differences 
between two groups when these were statistically significant. 
Pearson correlation test was used for correlation analyzes. 
p values <0.05 were considered as statistically significant.
 RESULTS
 There were 501 patients in conservative treatment 
group. 377 (75.24%) were female and 124 (24.75%) were 
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male. There were 312 patients in surgical treatment group. 
231 (74.03%) were female and 81 (25.96%) were male. The 
control group consisted of 152 patients, of whom 39 
(25.65%) were female and 113 (74.34%) were male. The 
mean ages of conservative treatment, surgical treatment 
and the control groups were 67±12, 63±11 and 74±2 years, 
respectively. The demographic features of the participants 
are shown at Table 1.
 CRP values of conservative treatment group and early 
phase surgical treatment group were higher than the 
control group (p=0.002). ESR values of early phase 
surgical treatment group were higher than those of the 
control group (p=0.043). No statistically significant 
differences were found between groups on other 
comparison (Tables 2, 3).
 Mean MPV values of conservative treatment group, 
early phase surgical treatment group, late phase surgical 
treatment group and the control group were 8.05±1.35 
(4.73-19.70) fl, 7.86±1.28 (4.72-13.30), 7.55±1.19 (4.77-
13.20) fl, and 7.50±1.35 (4.98-14.40) fl, respectively. 
Statistically significant differences on mean MPV values 
were determined between control and conservative 
treatment groups, and also early phase surgical treatment 
group (p=0.001, and p=0.005, respectively). No statistically 
significant difference was determined between control 
and late phase surgical treatment groups (p=0.796) 
(Tables 4). Statistically significant differences were 
determined in mean MPV values between conservative 
treatment and late phase surgical treatment groups 
(p=0.001), but no statistically significant difference was 
determined in late phase surgical treatment group 
(p=0.057) (Tables 2, 3).








Male n (%) 81 (25.96) 124 (75.24 86 (24.75)
Female n (%) 231 (74.03) 377 (45.0) 86 (45.0)
Age in years ± SD 63.85±11.68 67.14±12.99 74.55±2.60
Table 2: Comparison of MPV, ESR, CRP values between conservative treatment group and surgical treatment group
Variable Conservative treatment group
Surgical treatment group
Early phase (p) Late phase (p)
MPV (fL) 8.05±1.35 7.86±1.28 (0.057) 7.69±1.79 (0.001)
ESR (mm/h) 23.72±17.31 25.51±20.55 (0.418) 23.56±19.44 (0.963)
CRP (mg/dl) 1.282±3.220 2.019±3.158 (0.100) 0.877±1.155 (0.300)
Table 3: The comparison of MPV, ESR, CRP values between conservative treatment group  and the control group 
Variable Conservative treatment group Control group (p)
MPV (fL) 8.05±1.35 7.50±1.35 (0.000)
ESR (mm/h) 23.72±17.31 21.37±11.81 (0.061)
CRP (mg/dl) 1.282±3.220 0.661±0.708 (0.001)
Table 4: The comparison of MPV, ESR, CRP values between surgical treatment group and the control group
Variable Control group
Surgical treatment group
Early phase (p) Late phase (p)
MPV (fL) 7.50±1.35 7.86±1.28 (0.005) 7.69±1.79 (0.796)
ESR (mm/h) 21.37±11.81 25.51±20.55 (0.043) 23.56±19.44 (0.310)
CRP (mg/dl) 0.661±0.708 2.019±3.158 (0.002) 0.877±1.155 (0.185)
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 DISCUSSION
 OA, occurring mostly in advanced age, is a degenerative 
disease that affects articular cartilage and adjacent 
anatomical structures (15). Synovial cytokine generation 
and cartilage degeneration related symptoms begin 
before development of radiological findings. The 
inflammatory process of the synovitis contributes to the 
pathogenesis of OA (4,15). Increase in synovial fluid in the 
joint is associated with synovial activation. Aseptic 
loosening may be caused by increased synovial fluid in 
patients with total hip arthroplasty. During total hip 
arthroplasty sufficient excision of synovium, and other 
pathological tissues are important. However, sufficient 
removal of these tissues cannot be always achieved 
during surgery (19-21). Histological alterations associated 
with synovitis include synovial hyperplasia, macrophage 
and lymphocyte infiltration and fibrosis with the formation 
of new blood vessels in the synovium. Synovitis is an 
inflammatory event and contributes to the degenerative 
process (3,15). It also causes aseptic loosening of 
prosthetic joints applied into the degenerative area 
(19,20). MPV values increase in inflammatory events (14), 
which include other diseases such as diabetes mellitus, 
cerebral infarction, renal artery stenosis or preeclampsia 
(14,23). Also, CRP and ESR values change in inflammatory 
events (9,11).
 Increased MPV values show large and activated platelets. 
Large platelets are younger and more reactive, and they 
aggregate faster with adrenaline, collagen, and ADP than 
small platelets, and have higher densities granules. They 
have more capacity to produce and release prothrombotic 
and inflammatory agents such as trombaxan A2 and B2, 
serotonin and thromboglobulin than smaller platelets. 
There is a reverse correlation between MPV and platelet 
count. Thus, remain a certain level of total platelet mass 
can be ensured at (14,23,24).
 Platelet size is determined during megakaryocytopoiesis. 
This event is partially regulated by thrombopoietin. Growth 
factors and cytokines ensure production and reactivation of 
platelets in the bone marrow (25). Platelets can be affected 
by various biochemical processes and structural change 
occurs as a result. Inflammatory and prothrombotic agents 
which alter the microenvironment of platelets activate 
them. When this agents contact platelet membrane, volume 
increases and platelet shape changes from discoid to 
spherical (14,23,26). The lifetimes of platelets are about 
8-10 days (27).
 Serum MPV values may be used as a marker of 
inflammation in determining the severity of ostheoarthritis 
(28). However, degenerative changes in our patient cohort 
were Kellgren-Lawrence greade IV. All of our patients 
received regional anesthesia, and our literature search 
showed no relationship between the anesthetic management 
and serum MPV values.
 In our study, patients with OA have statistically significant 
higher mean MPV values than the control group. We 
believed that, these changes were caused by inflammatory 
process of joints. These findings support the notion that 
MPV values can be used as an inflammatory marker. If this 
hypothesis is correct, removal of inflammed tissues 
(sufficient excision of the capsule, synovium and other 
pathological tissues) in patients who undergo total hip 
arthroplasty should result in a decrease in MPV. The 
postoperative mean MPV values of patients with total hip 
artroplasty were lower than conservative treatment group. 
This difference was not statistically significant at early 
phase, but it became significant after one month. The early 
phase MPV values were derived from the postoperative 5-7 
days. We think that, because of platelet lifetime (8-10 days), 
the large platelets which were produced preoperatively due 
to inflammation persisted in the circulation, and newly 
generated platelets did not have time to replace them. 
Therefore, the changes in MPV values did not become 
significant in the early phase. However, sufficient time was 
allowed for new platelets to replace the inflammatory ones 
in the late phase, thus resulting in statistically significant 
differences.
 The main weakness of this study is its retrospective 
nature, and the results from a single center. A prospective 
evaluation of the same patient cohort may provide significant 
information to the management of total hip arthroplasty.
 In conclusion, MPV values are higher in OA. These 
increased values gradually decrease after surgery in 
patients undergoing total hip arthroplasty and return 
normal levels one month postoperatively. Increased MPV 
values can be associated with inflammatory process in OA, 
which can be cured by operative removal of inflamed joint 
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tissues and fluids. Also, if the capsule, inflammed synovium 
and other tissues cannot be sufficiently excised during 
surgery, reactivation of these pathological tissues and 
increase in joint fluid may occur. This situation may cause 
aseptic loosening of the prosthesis. We think that MPV 
values may be used as a predictive marker of this 
inflammatory reactivation after total hip arthroplasty. 
Further prospective, controlled, randomized studies are 
needed to evaluate the association between MPV and 
inflammatory reactivation following OA.
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